242 related articles for article (PubMed ID: 37432393)
1. Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice.
Collier JL; Pauken KE; Lee CAA; Patterson DG; Markson SC; Conway TS; Fung ME; France JA; Mucciarone KN; Lian CG; Murphy GF; Sharpe AH
J Exp Med; 2023 Oct; 220(10):. PubMed ID: 37432393
[TBL] [Abstract][Full Text] [Related]
2. Proteomic identification of MHC class I-associated peptidome derived from non-obese diabetic mouse thymus and pancreas.
Wang L; Li X; Yang S; Chen X; Li J; Wang S; Zhang M; Zheng Z; Zhou J; Wang L; Wu Y
J Proteomics; 2023 Jan; 270():104746. PubMed ID: 36210013
[TBL] [Abstract][Full Text] [Related]
3. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice.
Sgouroudis E; Albanese A; Piccirillo CA
J Immunol; 2008 Nov; 181(9):6283-92. PubMed ID: 18941219
[TBL] [Abstract][Full Text] [Related]
4. Footprint of pancreas infiltrating and circulating immune cells throughout type 1 diabetes development.
Bruggeman Y; Martens PJ; Sassi G; Viaene M; Wasserfall CH; Mathieu C; Gysemans C
Front Endocrinol (Lausanne); 2023; 14():1275316. PubMed ID: 38027120
[TBL] [Abstract][Full Text] [Related]
5. Genetic and therapeutic control of diabetogenic CD8+ T cells.
Santamaria P
Novartis Found Symp; 2008; 292():130-6; discussion 136-45, 202-3. PubMed ID: 19209463
[TBL] [Abstract][Full Text] [Related]
6. Transient Depletion of Foxp3
Watts D; Janßen M; Jaykar M; Palmucci F; Weigelt M; Petzold C; Hommel A; Sparwasser T; Bonifacio E; Kretschmer K
Front Immunol; 2021; 12():720133. PubMed ID: 34447385
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic and Immunoregulatory Activities of Extract of
Lin CH; Kuo YH; Shih CC
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373070
[TBL] [Abstract][Full Text] [Related]
8. Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.
Mattner J; Mohammed JP; Fusakio ME; Giessler C; Hackstein CP; Opoka R; Wrage M; Schey R; Clark J; Fraser HI; Rainbow DB; Wicker LS
PLoS Genet; 2019 Jun; 15(6):e1008178. PubMed ID: 31199784
[TBL] [Abstract][Full Text] [Related]
9. Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice.
Piccirillo CA; Tritt M; Sgouroudis E; Albanese A; Pyzik M; Hay V
Ann N Y Acad Sci; 2005 Jun; 1051():72-87. PubMed ID: 16126946
[TBL] [Abstract][Full Text] [Related]
10. Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant.
Martens PJ; Ellis D; Bruggeman Y; Viaene M; Laureys J; Teyton L; Mathieu C; Gysemans C
Front Endocrinol (Lausanne); 2022; 13():1023264. PubMed ID: 36339431
[TBL] [Abstract][Full Text] [Related]
11. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
12. B lymphocytes expressing high levels of PD-L1 are key regulators of diabetes development in non-obese diabetic mice.
Chen K; Xue Q; Liu F; Liu L; Yu C; Bian G; Zhang K; Fang C; Song J; Ju G; Wang J
Mol Immunol; 2019 Oct; 114():289-298. PubMed ID: 31419705
[TBL] [Abstract][Full Text] [Related]
13. T cell populations in the pancreatic lymph node naturally and consistently expand and contract in NOD mice as disease progresses.
Marrero I; Vong A; Dai Y; Davies JD
Mol Immunol; 2012 Aug; 52(1):9-18. PubMed ID: 22580347
[TBL] [Abstract][Full Text] [Related]
14. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.
Pauken KE; Jenkins MK; Azuma M; Fife BT
Diabetes; 2013 Aug; 62(8):2859-69. PubMed ID: 23545706
[TBL] [Abstract][Full Text] [Related]
15. Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage.
Diz R; Garland A; Vincent BG; Johnson MC; Spidale N; Wang B; Tisch R
PLoS One; 2012; 7(12):e52054. PubMed ID: 23251685
[TBL] [Abstract][Full Text] [Related]
16. Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice.
Yeh LT; Miaw SC; Lin MH; Chou FC; Shieh SJ; Chuang YP; Lin SH; Chang DM; Sytwu HK
J Immunol; 2013 Jul; 191(2):594-607. PubMed ID: 23752610
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M
J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316
[TBL] [Abstract][Full Text] [Related]
18. A TCR-like antibody against a proinsulin-containing fusion peptide ameliorates type 1 diabetes in NOD mice.
Matsumoto Y; Kishida K; Matsumoto M; Matsuoka S; Kohyama M; Suenaga T; Arase H
Biochem Biophys Res Commun; 2021 Jan; 534():680-686. PubMed ID: 33208230
[TBL] [Abstract][Full Text] [Related]
19. Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice.
Deng R; Khattar M; Xie A; Schroder PM; He X; Chen W; Stepkowski SM
Transplantation; 2014 Jun; 97(12):1216-24. PubMed ID: 24854475
[TBL] [Abstract][Full Text] [Related]
20. Reduction of T cell receptor diversity in NOD mice prevents development of type 1 diabetes but not Sjögren's syndrome.
Kern J; Drutel R; Leanhart S; Bogacz M; Pacholczyk R
PLoS One; 2014; 9(11):e112467. PubMed ID: 25379761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
